title: Effects of concomitant use of doxifluridine, radiotherapy and immunotherapy in patients with advanced cervical cancer.
abstract: Clinical effects of doxifluridine (group A, 600 mg/body/day; group B, 800 mg/body/day) combined with radiotherapy and immunotherapy were evaluated in patients with advanced cancer of the uterine cervix. Response rates were 84.2% (16/19 patients) in group A and 100% (18/18 patients) in group B, respectively (p=0.230). There was no significant difference in adverse reaction incidence between the methods but significantly higher grade adverse reaction were observed in group B than in group A (p=0.048). Time to progression (TTP) was longer in group B than in group A (p=0.081). The optimal 5'-DFUR dose was 800 mg/body (group B), by which higher grade adverse reactions were fully controlled and TTP was prolonged.
authors.affiliation: Department of Obstetrics and Gynecology, Kinki University School of Medicine, Osakasayama, Osaka 590-0132, Japan. yamamoto@sakai.med.kindai.ac.jp
authors.forename: K
authors.initials: K
authors.lastname: Yamamoto
authors.forename: K
authors.initials: K
authors.lastname: Noda
authors.forename: M
authors.initials: M
authors.lastname: Hatae
authors.forename: T
authors.initials: T
authors.lastname: Kudo
authors.forename: K
authors.initials: K
authors.lastname: Hasegawa
authors.forename: R
authors.initials: R
authors.lastname: Nishimura
authors.forename: H
authors.initials: H
authors.lastname: Honjo
authors.forename: A
authors.initials: A
authors.lastname: Yajima
authors.forename: S
authors.initials: S
authors.lastname: Sato
authors.forename: K
authors.initials: K
authors.lastname: Mizutani
authors.forename: M
authors.initials: M
authors.lastname: Yakushiji
authors.forename: Y
authors.initials: Y
authors.lastname: Terashima
authors.forename: K
authors.initials: K
authors.lastname: Ochiai
authors.forename: H
authors.initials: H
authors.lastname: Sasaki
authors.forename: M
authors.initials: M
authors.lastname: Ozaki
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D003131:Combined Modality Therapy; D016001:Confidence Intervals; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D005467:Floxuridine / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D012566:Sizofiran / Q000009:adverse effects / Q000627:therapeutic use*; D015996:Survival Rate; D013997:Time Factors; D002583:Uterine Cervical Neoplasms / Q000276:immunology / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy / Q000628:therapy*
chemical_list: D000970:Antineoplastic Agents; D005467:Floxuridine; D012566:Sizofiran; C025034:doxifluridine